Qiagen N.V.

NYSE:QGEN Stok Raporu

Piyasa değeri: US$7.3b

Qiagen Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Qiagen kazanç ve gelirin sırasıyla yıllık 12.4% ve 6.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 11.9% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 13.4% olacağı tahmin edilmektedir.

Anahtar bilgiler

12.4%

Kazanç büyüme oranı

11.91%

EPS büyüme oranı

Life Sciences kazanç büyümesi17.6%
Gelir büyüme oranı6.1%
Gelecekteki özkaynak getirisi13.41%
Analist kapsamı

Good

Son güncelleme18 May 2026

Gelecekteki son büyüme güncellemeleri

Analiz Makalesi • Nov 08

Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Shareholders might have noticed that Qiagen N.V. ( NYSE:QGEN ) filed its quarterly result this time last week. The...
Analiz Makalesi • Aug 08

Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours The...

Recent updates

Yeni Anlatı • May 15

Latent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects

Catalysts About Qiagen Qiagen provides molecular diagnostics, sample preparation and bioinformatics tools used in clinical testing and research. What are the underlying business or industry changes driving this perspective?
Yeni Anlatı • Apr 30

Latent Tuberculosis And Research Pressures Will Constrain Progress Yet Long-Term Prospects Remain Intact

Catalysts About Qiagen Qiagen provides sample preparation, diagnostic testing and bioinformatics tools for molecular and clinical laboratories. What are the underlying business or industry changes driving this perspective?
Anlatı Güncellemesi • Apr 29

QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostic Platform Expansion

Qiagen's analyst price target has been adjusted modestly lower to $53.53 from $55.46 as analysts factor in a slightly higher discount rate, a marginally different profit margin outlook, and recent target cuts and rating changes across major banks, alongside some upward revisions earlier in the period. Analyst Commentary Recent research shows a mix of optimism and caution around Qiagen, with several firms adjusting price targets in both directions and a few making rating changes.
Anlatı Güncellemesi • Apr 10

QGEN: I Expect Balance Sheet Strength To Drive Future Shareholder Returns

Qiagen's analyst price target is updated to $55.46. The modest change reflects mixed but generally constructive research commentary that cites an undemanding valuation, a robust balance sheet, and steady recent shareholder returns as key supports.
Anlatı Güncellemesi • Mar 27

QGEN: Possible Sale Prospects Are Expected To Drive Future Returns

The analyst price target for Qiagen has been nudged higher to $55.46 from $55.23, as analysts cite an undemanding valuation, a robust balance sheet, and a track record of average annual shareholder returns of 13% as key supports for the updated view. Analyst Commentary Recent research on Qiagen presents a mix of optimism and caution, with several firms adjusting ratings and price targets while focusing on valuation, balance sheet strength, and execution risk.
Anlatı Güncellemesi • Mar 12

QGEN: Possible Sale And Margin Upside Are Expected To Drive Future Returns

The Analyst Price Target on Qiagen has increased by $2, with analysts citing improved profit margin assumptions and a slightly lower future P/E multiple, while they refine discount rate and revenue growth inputs. Analyst Commentary Bullish and bearish analysts are split on Qiagen, with several firms lifting price targets while others trim estimates or ratings.
Anlatı Güncellemesi • Feb 25

QGEN: Possible Sale And Fresh Takeover Interest Will Drive Future Upside

Analysts have raised their blended price target for Qiagen by about $0.63 to $55.23. This reflects updated views on slightly different revenue growth, profit margin and future P/E assumptions after a mix of recent target increases and reductions across the Street.
Anlatı Güncellemesi • Feb 11

QGEN: Fairly Valued Outlook Will Hinge On Possible Sale And Execution Risks

Qiagen's analyst price target has edged up by about $1 to roughly $55, as analysts factor in slightly higher fair value and profit margin assumptions, along with a modest adjustment to growth expectations and P/E multiples. Analyst Commentary Recent Street research on Qiagen has been active, with several firms adjusting price targets in both directions and a few issuing downgrades.
Anlatı Güncellemesi • Jan 28

QGEN: Fairly Valued Outlook Will Depend On Possible Sale And Leadership Transition

Analysts have slightly raised their Qiagen price target to about $53.32 from $53.23, reflecting small tweaks to revenue growth, discount rate, profit margin, and future P/E assumptions following recent downgrades in Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target of about US$53.32 as still supported by long term earnings potential, even after recent revisions to revenue growth and profit margin assumptions.
Seeking Alpha • Jan 27

Qiagen: Takeover Optionality With A High-Quality Consumables Platform

Summary QGEN is a consumable molecular diagnostics and life-science tools platform. They offer QuantiFERON, QIAstat-Dx, QIAcuity dPCR, and QDI bioinformatics. Recently, there’s renewed takeover speculation after reports that show they’re weighing strategic options. QGEN’s potential fits include Danaher or Agilent, with Thermo Fisher less likely after the 2020 deal talks failed. QGEN’s portfolio with Parse Biosciences adds single-cell sequencing scale, while 2026 automation launches would further deepen its differentiated workflow. I think QGEN now makes much more sense given the renewed M&A interest. But if deal talks fail or rumors cool, shares could de-rate, so my “Buy” rating is explicitly speculative. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jan 08

QGEN: Fairly Valued Outlook Will Rely On Leadership Transition And Acquisitions

Narrative Update on Qiagen Analysts have lifted their Qiagen fair value estimate from approximately €50.43 to about €53.23, citing updated assumptions around revenue growth, profit margins and the P/E multiple applied to future earnings. What's in the News Qiagen plans a stock split or significant stock dividend with a 1 to 1.05263 ratio effective January 8, 2026, which adjusts the number of shares while keeping overall value aligned with the split terms (Key Developments).
Analiz Makalesi • Jan 07

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 21% Undervalued

Key Insights The projected fair value for Qiagen is US$59.66 based on 2 Stage Free Cash Flow to Equity Qiagen is...
Anlatı Güncellemesi • Dec 14

QGEN: Stable End Markets Will Support Gradual Sentiment Recovery Ahead

Analysts have trimmed their price target on Qiagen slightly, with a modest fair value reduction of about $0.36 per share. They cite still stable end markets, expectations for gradual improvement ahead, and a view that investment sentiment and valuations have largely bottomed.
Anlatı Güncellemesi • Nov 29

QGEN: Gradual Improvement Ahead As End Markets Remain Stable And Sentiment Bottoms

Analysts have modestly lowered their price target for Qiagen from $55 to $53 per share, citing stable end markets and expectations of gradual improvement ahead. Analyst Commentary Analysts have provided a balanced view of Qiagen's current outlook, highlighting both opportunities and ongoing challenges as the company navigates a gradually improving market environment.
Anlatı Güncellemesi • Nov 15

QGEN: Improving Sentiment And Stable Markets Will Set Stage For Future Upside

Analysts have slightly lowered their price target for Qiagen, reducing it by approximately $0.86 to reflect stable end markets. They also acknowledge that improvement is expected as investment sentiment stabilizes.
Analiz Makalesi • Nov 08

Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Shareholders might have noticed that Qiagen N.V. ( NYSE:QGEN ) filed its quarterly result this time last week. The...
Anlatı Güncellemesi • Oct 31

QGEN: Future Results Will Depend On Automation And Gradual Sentiment Recovery

Analysts have slightly lowered their price target for Qiagen from $55 to $53, citing stable end markets and anticipated gradual improvements in investment sentiment. Analyst Commentary Recent analyst updates highlight a nuanced outlook for Qiagen, with attention drawn to both its strengths and areas of potential risk in the near term.
Anlatı Güncellemesi • Oct 17

Syndromic Diagnostics And Automation Will Shape Future Healthcare

Analysts have slightly lowered their price target for Qiagen, reflecting a small decrease from $51.79 to $51.64 per share. They cite ongoing stability in end markets and expectations for gradual valuation improvement.
Anlatı Güncellemesi • Oct 03

Syndromic Diagnostics And Automation Will Shape Future Healthcare

Analysts have slightly reduced their fair value and price targets for Qiagen, with the consensus moving from approximately $52.39 to $51.79. This change is attributed to stabilizing end markets and expectations of gradual improvement in industry conditions.
Anlatı Güncellemesi • Sep 04

Syndromic Diagnostics And Automation Will Shape Future Healthcare

Analysts remain cautiously optimistic on Qiagen, citing modest macroeconomic improvements and solid company execution despite persistent sector headwinds, resulting in an unchanged consensus price target of $52.39. Analyst Commentary Bullish analysts cite modest improvements in macroeconomic conditions, including easing tariff concerns, as supportive of Qiagen's shares.
Analiz Makalesi • Sep 02

Qiagen's (NYSE:QGEN) Strong Earnings Are Of Good Quality

Qiagen N.V.'s ( NYSE:QGEN ) earnings announcement last week was disappointing for investors, despite the decent profit...
Analiz Makalesi • Aug 08

Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours The...
Analiz Makalesi • Aug 05

Qiagen N.V.'s (NYSE:QGEN) Share Price Could Signal Some Risk

NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours When close...
Seeking Alpha • Feb 25

Qiagen N.V.: Some Clarity Needed Before Buying The Dip

Summary Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's free cash flow improved markedly in FY 2024, and the company announced a $300 million stock buyback program last month. An analysis around Qiagen N.V. follows in the paragraphs below. Read the full article on Seeking Alpha

Kazanç ve Gelir Büyüme Tahminleri

NYSE:QGEN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/20282,40657255778312
12/31/20272,27246752974316
12/31/20262,15540649570516
3/31/20262,099402404615N/A
12/31/20252,090425447654N/A
9/30/20252,071405473658N/A
6/30/20252,040373496675N/A
3/31/20252,00394503680N/A
12/31/20241,97884502674N/A
9/30/20241,96693460633N/A
6/30/20241,94073405576N/A
3/31/20241,939337358521N/A
12/31/20231,965341297459N/A
9/30/20231,954332275432N/A
6/30/20231,978337376519N/A
3/31/20231,999353430580N/A
12/31/20222,142423566715N/A
9/30/20222,226488660826N/A
6/30/20222,261539580770N/A
3/31/20222,313563556755N/A
12/31/20212,252513432639N/A
9/30/20212,240311516745N/A
6/30/20212,190480337592N/A
3/31/20212,065449239571N/A
12/31/20201,870359154458N/A
9/30/20201,71319110298N/A
6/30/20201,61214108333N/A
3/31/20201,550-31152302N/A
12/31/20191,526-41N/A331N/A
9/30/20191,516-25N/A332N/A
6/30/20191,511196N/A342N/A
3/31/20191,507188N/A356N/A
12/31/20181,502190N/A359N/A
9/30/20181,49690N/A325N/A
6/30/20181,48278N/A324N/A
3/31/20181,45355N/A275N/A
12/31/20171,41840N/A287N/A
9/30/20171,38789N/A311N/A
6/30/20171,36275N/A323N/A
3/31/20171,34782N/A353N/A
12/31/20161,33880N/A342N/A
9/30/20161,320123N/A328N/A
6/30/20161,296123N/A331N/A
3/31/20161,281126N/A303N/A
12/31/20151,281130N/A317N/A
9/30/20151,293104N/A310N/A
6/30/20151,315105N/A303N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: QGEN 'nin tahmini kazanç büyümesi (yıllık 12.4% ) tasarruf oranının ( 3.5% ) üzerindedir.

Kazançlar ve Piyasa: QGEN şirketinin kazançlarının (yıllık 12.4% ) US pazarından (yıllık 16.8% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: QGEN şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: QGEN şirketinin gelirinin (yıllık 6.1% ) US pazarından (yıllık 11.7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: QGEN şirketinin gelirinin (yıllık 6.1% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: QGEN 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 13.4 %).

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/25 10:15
Gün Sonu Hisse Fiyatı2026/05/22 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Qiagen N.V. 42 Bu analistlerden 16, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Charles ButlerBarclays